<DOC>
	<DOC>NCT02989402</DOC>
	<brief_summary>This is a multicenter, prospective, phase IV study evaluating safety, tolerability and effectiveness of rivastigmine 27 mg -15 cm2 transdermal patch prescribed in patients with severe dementia of the Alzheimer's type as per discretion of treating physician.</brief_summary>
	<brief_title>A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>1. Patients willing to participate in the study by providing written informed consent. 2. Patients diagnosed with severe dementia secondary to Alzheimer's disease (AD) 3 .Patient's prescribed with rivastigmine 27mg 15 cm2 transdermal patch as per discretion of treating physician 1. Contraindication as per PI 2. Patients simultaneously participating in other studies 3. Use of other investigational drugs within 5 halflives of enrollment, or within 30 days (for small molecules) /until the expected PD effect has returned to baseline (for biologics)], whichever is longer. 4. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alzheimer, Rivastigmine</keyword>
</DOC>